-
<![CDATA[Clinical strategies for treating metastatic castration-sensitive prostate cancer]]>
17 Dec 2025 01:29 GMT
… of metastatic castration-sensitive prostate cancer (mCSPC). The conversation … prednisone, was discussed extensively for its long-standing role in metastatic prostate cancer … part of managing metastatic prostate cancer. Panelists reported routine use …
-
J&J positions its PARP combo Akeega in new prostate cancer subset with 2nd FDA nod
16 Dec 2025 00:48 GMT
… metastatic castration-sensitive prostate cancer (mCSPC).
Akeega, … prednisone to delay disease progression of the aggressive form of prostate cancer … options across the prostate cancer continuum," the … treatment landscape for prostate cancer has advanced in …
-
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
13 Dec 2025 01:56 GMT
… Prostate Cancer
Metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer … -mutated metastatic castration-resistant prostate cancer (mCRPC). AKEEGA® plus prednisone was approved by …
-
<![CDATA[FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer]]>
13 Dec 2025 01:28 GMT
… prostate cancer (mCSPC).1
This approval focuses on prostate cancer … -Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE). ClinicalTrials … acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC …
-
<![CDATA[FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer]]>
12 Dec 2025 22:45 GMT
… Akeega (abiraterone acetate) and prednisone (APP) for adults with deleterious … BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), as determined by … patients with prostate cancer with HRR mutations receiving Akeega plus prednisone, health- …
-
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer
12 Dec 2025 19:08 GMT
… (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or … -mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an … niraparib and abiraterone acetate plus prednisone (AAP) or placebo and AAP …
-
<![CDATA[FDA Greenlights Niraparib/Abiraterone Acetate With Prednisone in mHSPC]]>
12 Dec 2025 23:39 GMT
… acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer. FDA. December … abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients …
-
<![CDATA[FDA Approves Niraparib/Abiraterone Acetate Plus Prednisone for BRCA2+ mCSPC]]>
12 Dec 2025 23:12 GMT
… BRCA2-mutated metastatic castration-sensitive prostate cancer, as determined by an … and abiraterone acetate plus prednisone experienced a median radiographic … acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer. FDA. …
-
<![CDATA[Optimizing Androgen Signaling Blockade in High-Risk Prostate Cancer]]>
02 Dec 2025 04:50 GMT
… for locally advanced prostate cancer and high-risk biochemically relapsed prostate cancer. The findings … apalutamide, abiraterone acetate (Zytiga), and prednisone for 12 months.
Comparing the … abiraterone, you have to give prednisone along with it, and …
-
<![CDATA[Dr Smith on Future Research Directions in Prostate Cancer]]>
28 Nov 2025 20:42 GMT
… prostate cancer]. Unequivocally in metastatic castration-resistant prostate cancer … avenues in prostate cancer.
Smith began … castration-resistant prostate cancer, he … prednisone for the treatment of patients with metastatic castration-sensitive prostate cancer …
About
© 1995-2025